Navigation Links
Infinitus Clinical Research Consolidates- Sino-Indian CRO Enhances Core Capabilities
Date:2/1/2010

BANGALORE, India, February 1 /PRNewswire/ -- Infinitus Clinical Research is continuing to pioneer its unique strategy. This is based on the following elements:

    - Physician leadership
    - Employee ownership
    - Sino-Indian focus
    - Flexible co-development model availability
    - Experience of big Pharma drug development programme planning
    - Experience of early stage life science company product development
    - Phase I, II and III capability within Asia for clinical evaluation of
      drugs
    - Clinical evaluation of medical devices
    - Clinically focused bioinformatics capability
    - Unique academic links and collaborations

"As former Vice-President for clinical drug development with a major US Pharma company" said CEO, Roy Drucker, "I was frustrated by the unexploited potential of India and China. Large Western CROs were inevitably forced to give up part of the cost advantage of those countries because of operating expense back at base camp. The best local players scored better on price and satisfied study deadline requirements but were incapable of assuming a product development partnership role. We strive to deliver the best of both worlds at Infinitus. "

"Our conviction that excellent medical science underpins excellent clinical research is reflected in our European headquarters location in the Department of Pharmacology at Oxford University. We recognize that a significant part of our client base is in the USA and our North American office will open shortly. We are also progressing a major oncology initiative which will enable Infinitus to deliver unparalleled speed, quality and prices for studies in all phases."

"Infinitus has also recognized the opacity of India and China to smaller western companies wishing to conduct product or corporate transactions in these countries. With established strategic partners in both locations we are currently working with clients who have products for which they are seeking to achieve marketing presence in India and China, as well as executing M&A mandates on behalf of Western clients. More recently, we have begun to serve the needs of Chinese clients wishing to bring their products to the West."

Roy Drucker: "The world of clinical product development is changing very rapidly and there are huge advantages available to those who are prepared to explore unfamiliar territory. Infinitus can make that exploration a positive experience."

About Infinitus:

Infinitus executes its clinical research activities exclusively in Asia.

Benefitting from not having to bear the overheads of a large western infrastructure, the orientation is very much towards serving the needs of an international clientele which includes early stage life science companies researching pharmaceutical and biotechnology products as well as medical devices.

Operating out of Bangalore in India and Nanjing in China, it is led by a management team with extensive experience of conceiving and executing entire clinical product development programmes for global registration purposes, as well as substantial hands-on operational experience in the relevant territory.

Its objective is to assist in curtailing the cost of product development in its clinical stages while at the same time expediting execution and adding value in every way possible.

Infinitus' product candidate and program evaluation services are used as decision support tools by investors prior to investment or to guide investment decisions, and by pharmaceutical companies prior to committing their resources to clinical programs for candidates developed in-house or before in-licensing candidates. It is supported by Scientific Advisory Board members based in Oxford University.

    http://www.infinitusglobal.com

    Media Contact:
    Dr Shailendra
    Tel: +91-80-40051521
    E-mail: bd@infinitusglobal.com/ shailendra@infinitusglobal.com/
    varada@infinitusglobal.com

SOURCE Infinitus Clinical Research Pvt. Ltd.


'/>"/>
SOURCE Infinitus Clinical Research Pvt. Ltd.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Sequenom Announces Addition to Clinical Advisory Board
2. Conatus Pharmaceuticals Initiates Phase II Clinical Trial in Combination With Pegylated Interferon and Ribavirin for the Treatment of Hepatitis C Virus (HCV)
3. ChemoCentryx Initiates Clinical Trial of CCX168, A Novel Small Molecule C5aR Antagonist for the Treatment of Inflammatory and Autoimmune Diseases
4. Omeros Announces National Institute on Drug Abuses Support for Phase 2 Clinical Study in Addiction Program
5. Omnicare Clinical Research Licenses LiquentConnect to Create Added Value for Clients
6. Telik Announces Initiation of Phase 1 Clinical Study of Ezatiostat Hydrochloride (TELINTRA(R), TLK199) Tablets in Combination With Lenalidomide (Revlimid(R)) in Patients With Myelodysplastic Syndrome (MDS)
7. Steven Leventer Joins PharmaNet Development Group as Vice President, Clinical Research Neuroscience
8. Clinical Data Presented at Asia PCR/Sing LIVE Demonstrate Benefits of OrbusNeichs Genous(TM) Bio-engineered R stent(TM) in Challenging Patient Subsets
9. Michael J. Fox Foundation Awards $2.1 Million to Drive Six Industry Teams Pre-Clinical Development of Neuroprotective Parkinsons Therapies
10. Circassia Extends its Clinical-Stage Portfolio With Phase II Trials of T-Cell Vaccines Against House Dust Mite and Cat Allergies
11. ERT Demonstrates Patient Safety Expertise in Clinical Trials with New Knowledge Series of Papers
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/24/2017)... , Australien, 24. Februar 2017 ITL ... Unternehmen des Gesundheitsbereiches, ist erfreut, für das zum ... dem entsprechenden Vorjahreszeitraum exzellente Ergebnisse vorlegen zu können. ... Aktualisierung zum Wachstum" finden Sie hier . ... Gewinn nach Steuern 2,12 Millionen USD (Dez. 2015: 1,04 Millionen USD; +104 %) ...
(Date:2/24/2017)... 2017  Directors from Pharma To Market Pty Ltd and Ador ... resulting in the founding of Pharma To Market Pte Ltd, based ... are pleased to announce their expansion into Asia ... . The company are delighted to appoint Joelle Chia ... Singapore based entity. Joelle brings with her an ...
(Date:2/24/2017)... 2017 Non-alcoholic steatohepataitis (NASH) Pipeline ... drugs being developed for the treatment of ... that are in various phases of development ... on novel pharmacologic drugs & regenerative medicines ... recombinant proteins and RNA-based therapeutics, but excludes ...
Breaking Medicine Technology:
(Date:2/26/2017)... ... February 26, 2017 , ... NuevaCare, a leading home ... as Millbrae, Belmont, and Palo Alto, is proud to announce an important upgrade to ... consumers look for home care close to home, and by having city-specific pages, NuevaCare ...
(Date:2/26/2017)... ... , ... ODH, Inc.™ announced today it will exhibit and speak at ... Hotel in Arlington, VA. ODH’s director of medical strategy, Candace Saldarini, M.D., will present ... population health management. , ODH will also have an exhibit booth where attendees may ...
(Date:2/24/2017)... ... February 24, 2017 , ... ... TaskMate Go. Core benefits and advantages built into the home office sit stand ... look and feel. Ability to gain the benefits embedded in the TaskMate Go ...
(Date:2/24/2017)... ... February 24, 2017 , ... An in-depth computational analysis of genetic variants implicated ... to eight genes that may explain why susceptibility to one of the disorders could ... study published today in the journal npj Schizophrenia. , “There is a wealth ...
(Date:2/24/2017)... ... ... With millions of Americans and people worldwide struggling with ... aware of our options and are empowered with strength and information throughout the ... newest edition of "Vision and Hearing" in USA Today, that will educate readers ...
Breaking Medicine News(10 mins):